PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-65.74%
Both yoy net incomes decline, with AVXL at -26.32%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-40.21%
Negative yoy D&A while AVXL is 0.40%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
147.42%
Some yoy growth while AVXL is negative at -88.93%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-33.50%
Negative yoy SBC while AVXL is 485.06%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
2171.95%
Well above AVXL's 907.70% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
577.15%
AP growth of 577.15% while AVXL is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-447.03%
Negative yoy usage while AVXL is 907.70%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-33.50%
Both negative yoy, with AVXL at -46.93%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-13.29%
Both yoy CFO lines are negative, with AVXL at -0.21%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
19.79%
CapEx growth of 19.79% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
19.79%
We expand invests by 19.79% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-207.32%
We cut debt repayment yoy while AVXL is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
104.75%
Stock issuance far above AVXL's 184.42%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.